USTR lists Pinduoduo on Notorious Markets List
The US has added one of China’s biggest e-commerce platforms to its Notorious Markets List, which lists online markets which the US says are in violation of IP rights.
Pinduoduo.com has enjoyed rapid growth since it was founded in 2015, raising $1.6 billion through a public share offering in the US last July.
Yet the e-commerce platform is now the subject of US criticism over the sale of counterfeit goods on its site. Yesterday, April 25, the US Trade Representative (USTR) published its 2018 Notorious Markets List, which featured Pinduoduo for the first time.
According to the USTR, “a particularly common and pernicious form of counterfeit products on pinduoduo.com is so-called ‘Shanzhai’ products, also known as ‘parasite brands.’”
These ‘parasite brands’, the USTR said, “are products whose brand name and trademark imitate a legitimate brand”.
Although the report noted efforts by the company to tackle the listing of counterfeits on its site, the USTR said that these measures “fell short of fully addressing the problem” and urged Pinduoduo to do more to tackle trademark infringement.
The USTR Special 301 report, which identifies markets that fail to “adequately or effectively” ensure protection of IP rights, was also published yesterday.
In the report, the USTR placed Pinduoduo’s listing in the context of concerns over IP protection in China—a major source of tension between the American and Chinese governments.
“As China has become the largest e-commerce market in the world, widespread online piracy and counterfeiting in e-commerce markets represent critical concerns for US right holders”, the report said.
China recently implemented a new e-commerce legislation aimed at strengthening online trademark protection.
Last July, lawyers told WIPR that the law marked a positive step forward for rights owners in China.
The law makes e-commerce platforms such as Pinduoduo jointly responsible for counterfeits sold by third parties on their platforms.
The 301 report also sharply criticised the Canadian government’s plans to reform how the country regulates prices for patented drugs.
“If implemented, the changes would significantly undermine the marketplace for innovative pharmaceutical products”, the USTR said.
The report also noted that the USTR had obtained assurances from South Korea that it would bring its own regulation of drug prices in line with commitments made as part of the US-Korea Free Trade Agreement.
WIPR has contacted Pinduoduo for comment.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories like this sent straight to your inbox.
Today's top stories:
Exclusive data visualisation: Japanese firm biggest PCT filer
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk